Lifeward closes strategic partnership with Oramed

Lifeward Ltd. (NASDAQ: LFWD) announced it has completed its strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). The medical technology company acquired Oramed's clinical-stage Protein Oral Delivery technology through the transaction.

The partnership provides Lifeward with access to up to $47 million in capital from Oramed and certain investors. On March 25, 2026, Lifeward accessed $10 million of this capital, according to the company's statement.

Lifeward develops medical technology solutions for people with physical limitations or disabilities. The company's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit.

The company has made changes to its board of directors as part of the transaction. Additional details about the closing are available in Lifeward's Form 8-K filed on March 25, 2026.

Founded in 2001, Lifeward operates in the United States, Israel, and Germany. The company designs and commercializes rehabilitation and recovery solutions for clinical settings, homes, and communities.

You May Also Be Interested In

• Anthropic PBC: adjusted operating income increased for the three months ended September 30, 2026 to $2.5 billion
• Telos names Mark Griffin as CEO, John Wood moves to chairman
• Rhythm Pharmaceuticals revises LG Chem license deal, secures $750M loan